Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Companyâ€™s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
03/07/26	SEK 4.070	+0.25%	155,448
02/07/26	SEK 4.060	-4.92%	324,605
01/07/26	SEK 4.270	+3.14%	252,892
30/06/26	SEK 4.140	-3.72%	473,841
29/06/26	SEK 4.300	-3.37%	206,425

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 02:00:00 04/07/26 am AEST			5-day change	1st Jan Change
4.070 ^SEK	+0.25%		-8.54%	+176.87%

26/06	Four stocks have so far today posted new 52-week highs on the Stockholm Stock Exchange	FW
18/06	Nine stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW

Market Cap	429M 44.53M 38.92M 35.77M 33.34M 63.24M 4.24B 64.2M 167M 2.08B 167M 164M 7.18B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	429M 44.53M 38.92M 35.77M 33.34M 63.24M 4.24B 64.2M 167M 2.08B 167M 164M 7.18B	EV / Sales 2026 *	5.06x	EV / Sales 2027 *	2.77x
Free-Float	64.78%	Yield 2026 *	-	Yield 2027 *	-

26/06	Four stocks have so far today posted new 52-week highs on the Stockholm Stock Exchange	FW
18/06	Nine stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
16/06	Three stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
09/06	Calendar: Tuesday, June 9	FW
08/06	Calendar Tuesday June 9	FW
13/05	Sprint Bioscience Q1 operating loss SEK 14.3 mln	RE
13/05	Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Sprint Bioscience completes strategic evaluation of STK25 program	RE
16/04	Sprint Bioscience and Experimental Drug Development Centre Complete Strategic STK25 Evaluation	CI
14/04	21 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW
10/04	15 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW
08/04	17 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW
07/04	Nine stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW

04/06	Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company	AQ
19/05	Sprint Bioscience (Q1 Review): Momentum in the business	AQ
16/04	Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication	AQ
01/04	Sprint Bioscience appoints Jenni Björnulfson as CFO	AQ
01/04	Positive results expand the NNMT program into Chronic Kidney Disease	AQ

Sprint Bioscience AB Stock

Stocks

SPRINT

SE0006343745

Biotechnology & Medical Research

Valuation: Sprint Bioscience AB

Chart: Sprint Bioscience AB

Latest news : Sprint Bioscience AB

Analysts' recommendations: Sprint Bioscience AB

Press Releases: Sprint Bioscience AB

Quotes and Performance

Course Extremes

Managers and Directors: Sprint Bioscience AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

1 day	+0.25%
1 week	-8.54%
Current month	-1.69%
1 month	+22.96%
3 months	+62.80%
6 months	+173.15%
Current year	+176.87%

1 week	3.95	4.42
1 month	3.2	4.59
Current year	1.36	4.59
1 year	0.48	4.59
3 years	0.36	4.59
5 years	0.36	9.36
10 years	0.36	58

Manager	Title	Age	Since
Johan Emilsson CEO	Chief Executive Officer	42	01/10/2023
Martin Andersson CTO	Chief Tech/Sci/R&D Officer	55	01/01/2009
Jenni Björnulfson DFI	Director of Finance/CFO	55	04/05/2026

Director	Title	Age	Since
Svein Arild Mathisen BRD	Director/Board Member	70	01/01/2020
Björn Magnus Sjöstrand CHM	Chairman	58	01/01/2021
Fredrik Lehmann BRD	Director/Board Member	50	01/01/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPRINT BIOSCIENCE AB	+0.25%	-8.54%	+694.92%	+665.04%	44.53M
ARGENX SE	+0.68%	+5.92%	+77.86%	+139.22%	59.1B
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.26%	+91.40%	55.19B
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	24.67B
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+43.36%	-4.67%	19.69B
GENMAB A/S	-0.29%	+9.78%	+43.90%	-28.41%	17.56B
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+186.15%	+361.42%	16.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+37.85%	-	14.84B
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	14.04B
Average	+2.61%	+6.86%	+118.31%	+204.92%	24.55B
Weighted average by Cap.	+2.46%	+6.47%	+58.44%	+137.08%

	2026 *	2027 *
Net sales	84.8M 8.79M 7.69M 7.06M 6.58M 12.49M 837M 12.68M 32.97M 412M 33M 32.29M 1.42B	155M 16.07M 14.05M 12.91M 12.03M 22.83M 1.53B 23.17M 60.26M 752M 60.32M 59.03M 2.59B
Net income	-	-
Net Debt	-	-